KM257 for advanced HER2-positive or HER2-expressing solid cancers
Part of Cancer clinical trials.
This early-stage study tests KM257, a new cancer treatment, in people with advanced solid tumors that are HER2-positive or HER2-expressing. The goal is to see how well it can work and how safe it is.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 to 75 and can understand the study and sign consent
- You have advanced solid cancer confirmed by lab tests (tissue or cells)
- Your tumor is HER2-positive or HER2-expressing
- You can be active in daily life (ECOG 0–1) and expect to live at least 12 weeks
- Heart/lung/liver/kidney tests must be acceptable, and you must be able to use reliable birth control if applicable
- You must have either at least one measurable tumor spot (or—if allowed in your study part—a tumor spot that can be tracked even if it’s not measurable)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests KM602, a new study treatment, in people with advanced solid tumors like melanoma or non-small cell lung cancer that have progressed after standard treatments. If you qualify, the goal is to see how the drug works and how safe it is in early research.
This study tests a new antibody-drug conjugate (FDA022-BB05) for people with advanced solid cancers—especially breast, endometrial, bladder, colorectal, or lung cancer—that have stopped responding to standard therapy. The drug targets HER2, a protein on some cancer cells, to try to shrink tumors or slow their growth.
This early-phase study tests KM501, a treatment targeting HER2, in adults with solid cancers that have worsened and for which standard treatment isn’t available or not tolerated. The goal is to see whether KM501 is safe and whether it can shrink or control the cancer in this group.
This Phase 3 study tests whether taking KN026 with HB1801 as first treatment works better and is safe for people with HER2-positive breast cancer that has come back or spread. It may help by improving tumor response and delaying progression compared with the study’s treatment plan.
This trial tests a new drug called JSKN027 for people with advanced solid tumors (cancers that have spread) that have not responded to standard treatments. The goal is to see if the drug is safe and can help shrink tumors.
This Phase 1 trial tests KH617, a new treatment, in adults with advanced cancers to see if it can be given safely and whether it shows signs of benefit. It is especially focused on tumors that have few or no standard treatment options, including certain brain tumor recurrences.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.